The Alzheimer’s Drug Discovery Foundation (ADDF) announced a second round of research awards totaling about $6 million, part of its Diagnostics Accelerator initiative into better diagnostics for Alzheimer’s (AD) and related dementia. These six global investigative efforts are in various stages of development, and include an advanced blood…
Longer sequence repeats in or near two genes may be linked to a higher risk of late-onset Alzheimer’s disease, a study reports. The study “Alzheimer Disease Pathology-Associated Polymorphism in a Complex Variable Number of Tandem Repeat Region Within the MUC6 Gene, Near the AP2A2 Gene” was…
INmune Bio has dosed the first patient in its Phase 1b trial (NCT03943264) testing the safety and efficacy of its next-generation anti-inflammatory compound XPro1595 for Alzheimer’s disease (AD). The trial is currently recruiting in different sites across Australia. More information can be found here. Instead…
A potential oral treatment for agitation due to Alzheimer’s dementia, AVP-786, will continue in advanced clinical testing after a fuller analysis of data from two completed Phase 3 trials, Avanir Pharmaceuticals said. Their results were conflicting, with one trial showing a significant easing of agitated behaviors in patients given a…
The Bluefield Project to Cure FTD will receive $1.2 million from the Alzheimer’s Drug Discovery Foundation (ADDF) to validate an exploratory blood test in frontotemporal dementia (FTD). The award is the first FTD investment through the foundation’s Diagnostics Accelerator, a venture philanthropy vehicle to advance the development…
Biohaven announced that its Phase 2/3 study of the investigational oral therapy troriluzole (BHV-4157) in treating symptoms of mild to moderate Alzheimer’s disease (AD) has fully enrolled more than 700 patients. The T2 Protect AD trial will assess if troriluzole use can protect against or slow…
A newly opened Phase 2 clinical trial will test the sensitivity of new imaging tool for plaque buildup in the brains of people with mild cognitive impairment and dementia due to Alzheimer’s disease, Aprinoia Therapeutics announced. The trial is set to enroll 130 adults, 50 to 85 years old, a…
The Alzheimer’s Association and the African Methodist Episcopal Church (AME Church) announced a three-year partnership to promote greater involvement in the fight against Alzheimer’s (AD) and to heighten awareness of the support needed by patients and their families. Through the leadership of its International Health Commission, the…
The second part of a clinical study evaluating the use of a blood diagnostic test for Alzheimer’s disease — called the Lymphocyte Proliferation Test (LymPro Test) — is now fully enrolled, the trial’s sponsor, Breakthrough Diagnostics, announced. The trial is ongoing at Leipzig University in Germany, and top-line results…
The National Institutes of Health (NIH) has awarded the Alzheimer’s Association $1.34 million to find more evidence-based ways to enhance care and support for those with Alzheimer’s disease (AD) or other dementias, and their care partners. The five-year grant will support a project titled “Leveraging an Interdisciplinary Consortium…
Get regular updates to your inbox.